Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

Sponsor
University of Ulm
Study ID
NCT06233357
Status
Completed

Conditions

  • COVID-19
  • Critically Ill
  • Interleukin 6
  • Outcome, Fatal
  • Tocilizumab

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In a retrospective observational study, critically ill COVID-19 patients admitted to the ICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated (ethics application nr. 129/22 of the ethics commssion of the university Ulm.

Key Dates

Start date
Aug 1, 2021
Status verified
Jan 2024
Primary completion
Apr 28, 2022
Completion
Dec 31, 2023

Study Design

Enrollment
95 participants (actual)

Arms

  • Arm: N, no casirivimab / imdevimab or tocilizumab
    No intervention
  • Arm: C, treated with casirivimab / imdevimab
    Active comparator
  • Arm: T, Treated with Tocilizumab
    Active comparator
  • Arm: C + T, treated with casirivimab / imdevimab and tocilizumab
    Active comparator

Primary Outcome Measure

Mortality rates in the 4 groups [ Time Frame: 28-day mortality ]

Related Studies